Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future
J.M. Carrascosa, Ira Jacobs, Danielle Petersel, et al.
Dermatology and Therapy (2018) Vol. 8, Iss. 2, pp. 173-194
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

AURIEL ‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis
Jana Hercogová, Kim Papp, V. Chyrok, et al.
British Journal of Dermatology (2019) Vol. 182, Iss. 2, pp. 316-326
Open Access | Times Cited: 59
Taxifolin attenuates IMQ-induced murine psoriasis-like dermatitis by regulating T helper cell responses via Notch1 and JAK2/STAT3 signal pathways
Xiaohong Yuan, Ning Li, Miaomiao Zhang, et al.
Biomedicine & Pharmacotherapy (2019) Vol. 123, pp. 109747-109747
Open Access | Times Cited: 44
Therapeutic Development Based on the Immunopathogenic Mechanisms of Psoriasis
Jen-Chih Tseng, Yung-Chi Chang, Chun‐Ming Huang, et al.
Pharmaceutics (2021) Vol. 13, Iss. 7, pp. 1064-1064
Open Access | Times Cited: 36
Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases
Rodrigo F. N. Ribeiro, Cláudia Cavadas, Maria Manuel Silva
Drug Discovery Today (2021) Vol. 26, Iss. 7, pp. 1620-1641
Closed Access | Times Cited: 32
An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review
Seenu M. Hariprasad, Richard Gale, Christina Y. Weng, et al.
Ophthalmology and Therapy (2022) Vol. 11, Iss. 3, pp. 959-982
Open Access | Times Cited: 22
Therapeutic Fusion Proteins
Morgan C. Marsh, Shawn C. Owen
The AAPS Journal (2023) Vol. 26, Iss. 1
Closed Access | Times Cited: 11
Biosimilars for the treatment of psoriasis
L. Puig, A. López‐Ferrer
Expert Opinion on Biological Therapy (2019) Vol. 19, Iss. 10, pp. 993-1000
Closed Access | Times Cited: 33
Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience
Juliet N. Barker, Giampiero Girolomoni, Alexander Egeberg, et al.
Journal of Dermatological Treatment (2019) Vol. 31, Iss. 8, pp. 794-800
Open Access | Times Cited: 32
Novel archetype in psoriasis management bridging molecular dynamics in exploring novel therapies
Krishna Yadav, Deependra Singh, Manju Rawat Singh
European Journal of Pharmacology (2021) Vol. 907, pp. 174254-174254
Closed Access | Times Cited: 24
Current and emerging prospects in the psoriatic treatment
Rutuja Vilas Nikam, M Gowtham, Pratiksha Sanjay More, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110331-110331
Closed Access | Times Cited: 10
Biosimilars for the treatment of psoriasis: a narrative review
Duc Binh Phan, Z.Z.N. Yiu
Italian Journal of Dermatology and Venereology (2025) Vol. 159, Iss. 6
Closed Access
Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme
Ran Jin, James Haughton, Emily J. Goddard, et al.
Rheumatology and Therapy (2025)
Open Access
Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice
Niels S. Vermeer, Thijs J. Giezen, Sofia Zastavnik, et al.
Clinical Pharmacology & Therapeutics (2018) Vol. 105, Iss. 4, pp. 962-969
Open Access | Times Cited: 32
Guselkumab: A Review in Moderate to Severe Plaque Psoriasis
Zaina T. Al-Salama, Lesley J. Scott
American Journal of Clinical Dermatology (2018) Vol. 19, Iss. 6, pp. 907-918
Closed Access | Times Cited: 28
TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis
Paolo Gisondi, Davide Geat, Andrea Conti, et al.
Expert Review of Clinical Immunology (2020) Vol. 16, Iss. 6, pp. 591-598
Closed Access | Times Cited: 25
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
Giampiero Girolomoni, L. Savage, Paolo Gisondi, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 10, pp. 2171-2185
Open Access | Times Cited: 8
Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region
Khalid A. Alnaqbi, Nasra Al Adhoubi, Sara Al Dallal, et al.
BioDrugs (2024) Vol. 38, Iss. 3, pp. 449-463
Open Access | Times Cited: 3
PSORI-CM02 alleviates IMQ-induced mouse dermatitis via differentially regulating pro- and anti-inflammatory cytokines targeting of Th2 specific transcript factor GATA3
Dinghong Wu, Miaomiao Zhang, Ning Li, et al.
Biomedicine & Pharmacotherapy (2018) Vol. 110, pp. 265-274
Open Access | Times Cited: 26
<p>Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date</p>
Marco Galluzzo, S. D’Adamio, Antonio Massaro, et al.
Clinical Cosmetic and Investigational Dermatology (2019) Vol. Volume 12, pp. 311-321
Open Access | Times Cited: 24
Treatments for psoriasis: A journey from classical to advanced therapies. How far have we reached?
Gangadhar Hari, Anoop Kishore, K. Sreedhara Ranganath Pai
European Journal of Pharmacology (2022) Vol. 929, pp. 175147-175147
Closed Access | Times Cited: 14
Belgian recommendations for managing psoriasis in a changing treatment landscape
Reinhart Speeckaert, Arjen Nikkels, Jo Lambert, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 2
Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis
Kelly A. Reynolds, Deeti J. Pithadia, Erica B. Lee, et al.
American Journal of Clinical Dermatology (2020) Vol. 21, Iss. 4, pp. 483-491
Closed Access | Times Cited: 18
Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study
Alan Menter, Petr Arenberger, Sigrid Balser, et al.
Expert Opinion on Biological Therapy (2020) Vol. 21, Iss. 1, pp. 87-96
Open Access | Times Cited: 18
Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis
Rachel C. Ruda, Katherine A. Kelly, Steven R. Feldman
Journal of Dermatological Treatment (2022) Vol. 34, Iss. 1
Open Access | Times Cited: 10
Phenotypic changes of lymphocyte populations in psoriasiform dermatitis animal model
Mihaela Surcel, Radu‐Ionuț Huică, Adriana Munteanu, et al.
Experimental and Therapeutic Medicine (2018)
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top